首页 > 市场调查报告书 > 製药

疫苗

市场调查报告书

商品编码

1741100

经鼻吸入型疫苗市场：依疫苗类型、应用、通路和地区划分

Nasal Vaccines Market, By Vaccine Type, By Application, By Distribution Channel, By Geography

出版日期: 2025年03月26日 | 出版商:

Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2025 年经鼻吸入型疫苗市场价值估计为 4.918 亿美元，预计到 2032 年将达到 8.762 亿美元，2025 年至 2032 年的复合年增长率为 8.6%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	4.918亿美元
效能数据	从2020年到2024年	预测期	2025年至2032年
预测期：2025-2032年复合年增长率：	8.60%	2032年价值预测	8.762亿美元

经鼻吸入型疫苗是透过鼻腔给药的疫苗，无需注射即可刺激免疫反应。这种疫苗是透过鼻腔给药，而不是口服或透过手臂给药。目前有几种版本的经鼻吸入型疫苗正在研发中，但大多数处于临床前阶段。由于经鼻吸入型疫苗是透过鼻腔给药的，而病毒正是从鼻腔进入人体的，因此它们被吹捧为能够阻止感染循环、阻断感染、阻止肺部损伤以及其他副作用。因此，市场相关人员正致力于开发安全有效的经鼻吸入型疫苗。

市场动态：

呼吸系统疾病和感染疾病负担的增加、COVID-19 的爆发、对安全有效疫苗开发的关注度的提高、对安全有效疫苗的需求不断增长以及研发活动的活性化是预计在预测期内推动全球鼻腔疫苗市场增长的关键因素。

例如，2023年1月，总部位于印度的全球生物製药公司巴拉特生物技术公司（Bharat Biotech）宣布在印度推出首款经鼻新冠疫苗iNCOVACC，该疫苗不仅可用于基础剂量，还可用于异源（混合搭配）加强剂量。 iNCOVACC是首个核准作为两剂基础剂量，并在两剂新冠疫苗或新冠疫苗（COVAXIN）后作为异源加强剂量的经鼻新冠疫苗。该疫苗已获得印度药品监督管理局（DCGI）核准，可作为异源加强剂量。新型iNCOVACC疫苗可能彻底改变对抗新冠感染的方式。

本研究的主要特点

本报告对全球经鼻吸入型疫苗市场进行了详细分析，并以 2024 年为基准年，展示了预测期（2025-2032 年）的市场规模和复合年增长率。
它还强调了不同领域的潜在收益成长机会，并说明了该市场的引人注目的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的主要考察。
全球鼻腔疫苗市场的主要企业已根据以下参数、公司亮点、产品系列、关键亮点、绩效和策略进行了分析：
该研究涉及的主要企业包括阿斯特捷利康、葛兰素史克、辉瑞、印度血清研究所私人有限公司、科兴生物、巴拉特生物技术、Altimmune、FluGen Inc.、Vaxart、Intravac、Gamma Vaccines Pty Ltd. 和 BioNTech SE。
本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
全球鼻腔疫苗市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员将透过用于分析全球鼻腔疫苗市场的各种策略矩阵来做出决策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 491.8 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	8.60%	2032 Value Projection:	USD 876.2 Mn

Nasal vaccine is a vaccine administered through the nose that stimulates an immune response without an injection. A vaccine dose is given via nose, rather than orally or through the arm. While several versions of a nasal vaccine are in development, most are in preclinical stages. A nasal vaccine is touted to have the ability to end the cycle of transmission, stop infection, and stop lung damage, including other adverse effects as the dose is administered through the nose, where the virus first enters the body. Thus, market players are focusing on developing safe/effective nasal vaccines.

Market Dynamics:

The rising burden of respiratory diseases or infections, outbreak of COVID-19, increasing focus on the development of safe and effective vaccines, increasing demand for safe and effective vaccines, and increasing research and development activities are the major factors expected to propel the growth of the global nasal vaccines market over the forecast period.

For instance, in January 2023, Bharat Biotech, an Indian-based global biopharmaceutical company announced the launch of India's first intra-nasal COVID-19 vaccine, iNCOVACC for a primary as well as heterologous (mix-and-match) booster dose in India. It was the first nasal COVID-19 vaccine that was approved both as a primary two-dose regimen, and a heterologous booster after two doses of Covishield or Covaxin. It is approved by the Drugs Control General of India (DCGI) as a heterologous booster dose. The new iNCOVACC vaccine can potentially revolutionize the battle against COVID-19 infection.

Key Features of the Study:

This report provides an in-depth analysis of the global nasal vaccines market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global nasal vaccines market based on the following parameters, company highlights, products portfolio, key highlights, financial performance, and strategies
The key companies covered as a part of this study include AstraZeneca, GlaxoSmithKline plc, Pfizer Inc., Serum Institute of India Pvt. Ltd., SINOVAC, Bharat Biotech, Altimmune, FluGen Inc., Vaxart, Intravacc, Gamma Vaccines Pty Ltd., and BioNTech SE
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global nasal vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nasal vaccines market

Detailed Segmentation:

By Vaccine Type:
- Live Attenuated Vaccines
- Inactivated Vaccines
- Subunit, Recombinant, and Conjugate Vaccines
- Others (such as DNA Vaccines, Viral Vector Vaccines, etc.)
By Application:
- Influenza
- COVID-19
- Other Respiratory Infections (such as RSV, Pneumococcal, etc.)
- Others (such as Cholera, Typhoid, etc.)
By Distribution Channel:
- Public
- Private
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- AstraZeneca,
- GlaxoSmithKline plc
- Pfizer Inc.
- Serum Institute of India Pvt. Ltd.
- SINOVAC
- Bharat Biotech
- Altimmune
- FluGen Inc.
- Vaxart
- Intravacc
- Gamma Vaccines Pty Ltd.
- BioNTech SE

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Nasal Vaccines Market, By Vaccine Type
- Global Nasal Vaccines Market, By Application
- Global Nasal Vaccines Market, By Distribution Channel
- Global Nasal Vaccines Market, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Rising burden of respiratory diseases or infections
- Lack of healthcare infrastructure in developing economies
- Increasing demand for safe and effective vaccines
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Nasal Vaccines Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Nasal Vaccines Market, By Vaccine Type, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Live Attenuated Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Inactivated Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Subunit, Recombinant, and Conjugate Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Others (such as DNA Vaccines, Viral Vector Vaccines, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

6. Global Nasal Vaccines Market, By Application, 2020-2028, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Influenza
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
COVID-19
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Other Respiratory Infections (such as RSV, Pneumococcal, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Others (such as Cholera, Typhoid, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

7. Global Nasal Vaccines Market, By Distribution Channel, 2025-2028, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

8. Global Nasal Vaccines Market, By Region, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Serum Institute of India Pvt. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
SINOVAC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bharat Biotech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Altimmune
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
FluGen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Vaxart
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Intravacc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Gamma Vaccines Pty Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
BioNTech SE
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Analyst Views

10. Section

Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

经鼻吸入型疫苗市场：依疫苗类型、应用、通路和地区划分